Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CSHP Top 40 Topics for Seminar 2008
2) Anticoagulation
25) Medication Errors
26) Medication Safety
32) Pediatrics
34) Pharmacy Law Update
http://seminar.cshp.org/uploads/Cat/Prospectus.pdf
CDEX Events
October 9-12, 2008 California Society of Health-System Pharmacists Show in Anaheim, CA.
http://cdexinc.com/
Seminar 2008 offers the latest information on a wide range of clinical and research breakthroughs, procedures and issues for pharmacists, technicians and students. From presentations to receptions, Seminar has found the perfect balance of content and networking for professional growth and inspiration.
http://seminar.cshp.org/
CSHP site: 2008
http://www.cshp.org/uploads/file/Newsroom/2008/MERP%20meeting%209%2008%20Sac%20_2_%20_2_.pdf
http://archive.constantcontact.com/fs091/1102078811954/archive/1102265242676.html
http://www.cshp.org/index.php?page=seminar-and-meetings
http://www.cshp.org/index.php?page=technicians-and-students-2
http://www.cshp.org/index.php?page=government-advocacy
ABMI CORP.
All Business Machines, Inc.
2555 3rd Street, Suite 100
Sacramento, California 95818
Voice: 916.325.7800
Voice: 888.880.7801
Fax: 916.444.2354
Email: info@allbusinessmachines.com
Website: http://www.allbusinessmachines.com
http://cdexinc.com/pages/meddistributor.html
Some healthcare facilities with ValiMed
Cedars-Sinai Medical Center (Los Angeles, California)
Stanford Hospitals and Clinics (Stanford, California)
U.C. Davis Health System (Sacramento, California)
Veterans Administration Hospital (Palo Alto, California)
http://cdexinc.com/pages/medresources.html
Hospitals with Contracts for Purchase or Lease of one or more CDEX ValiMed™ Medication Validation Systems
(February 29, 2007)
All Children’s Hospital, Inc. (St. Petersburg, Florida)
Children’s Hospitals and Clinics of Minnesota (Minneapolis, Minnesota)
Children’s Hospitals and Clinics of Minnesota (St. Paul, Minnesota)
Children’s Medical Center of Dallas (Dallas Texas)
Cleveland Clinic Foundation (Cleveland, Ohio)
Henry Ford Health System (Detroit, Michigan)
Loyola University Medical Center (Maywood, Illinois)
Mount Carmel Health System (Columbus, Ohio)
Primary Children’s Medical Center (Salt Lake City, Utah)
Stanford Hospitals and Clinics (Stanford, California)
U.C. Davis Health System (Sacramento, California)
University of Maryland Medical Center (Baltimore, Maryland)
University of Michigan Health System (Ann Arbor, Michigan)
University of Utah Hospitals and Clinics (Salt Lake City, Utah)
Veterans Administration Hospital (Palo Alto, California)
Children's Hospital of The King's Daughters (Norfolk, VA)
Bronson Methodist Hospital (Kalamazoo, MI)
East Jefferson General Hospital (Metairie, LA)
Analytical Spectral Devices, Inc. and CDEX announce settlement agreement
Boulder, Colo., September 29 , 2006 — CDEX Inc. and Analytical Spectral Devices, Inc. announced today that they entered into a settlement agreement with regards to Civil Action No. 06-CV-426-RDB-CBS that was pending before the U.S. Federal District Court in Denver, Colorado. As part of the Settlement Agreement, CDEX has been fully licensed under ASD’s patent for liquid pharmaceuticals. CDEX acknowledges the validity of ASD’s patent and such acknowledgement shall continue for as long as the license remains in effect. In consideration of the settlement agreement, both parties have agreed to dismiss their respective claims against each other. The terms and conditions of the settlement agreement are otherwise confidential.
http://asdi.com/news-pr_CDEX%20lawsuit%20settlement_9-29-06.asp
U.S. Federal District Court Dismisses ASD and CDEX Lawsuits with Prejudice
ROCKVILLE, Md., Oct 03, 2006 (BUSINESS WIRE) -- CDEX Inc. (OTCBB: CEXI)
announced today that the U.S. Federal District Court in Denver, Colorado has
reviewed and approved the Stipulation to Dismiss that was filed in the Court on
September 29, 2006 as part of a settlement agreement reached between ASD and
CDEX with regards to Civil Action No. 06-CV-426-RDB-CBS. Today, the Court
entered an Order of Dismissal with Prejudice and vacated all pending actions
before the Court.
This action by the Court brings to a final end the patent infringement lawsuit
that was filed by ASD against CDEX. It also brings to a final close CDEX's
counterclaims of invalidity and unenforceability that the company filed in
response to ASD's lawsuit.
"This case was settled in a manner that was fair and equitable to both parties,
while preserving the company's rights and protecting the interests of our
shareholders," said Jim Griffin, CDEX President and CEO.
About CDEX Inc.
CDEX Inc. is a chemical detection technology development company that uses its
expertise to develop and market life safety/public safety products for the
healthcare, homeland security, and brand protection markets. CDEX's ValiMed
Medication Validation System is used for quality assurance to ensure that
high-risk medications that are compounded in hospital pharmacies are the correct
medication, in the correct concentration, and correct diluent before they are
administered to patients. CDEX technology can be used in homeland security
market applications to identify suspicious substances such as trace amounts of
explosives, in liquid or solid form, and illegal drugs for law enforcement in
the homeland security market. CDEX is headquartered in Rockville, Maryland with
its research and development laboratory, engineering, and manufacturing
operations in Tucson, Arizona. For more information, visit www.cdex-inc.com.
Any statements made in this press release which contain information that is not
historical are essentially forward-looking. Many forward-looking statements can
be identified by the use of words such as "expects," "plans," "may,"
"anticipates," "believes," "should," "intends," "estimates," and other words of
similar meaning. These statements are subject to risks and uncertainties that
cannot be predicted or quantified and, consequently, actual results may differ
materially from those expressed or implied by such forward-looking statements.
Such risks are detailed from time-to-time in filings with the Securities and
Exchange Commission. There is no obligation to publicly update any
forward-looking statements.
SOURCE: CDEX, Inc.
CDEX Quarterly Report September 13, 2006.
http://www.sec.gov/Archives/edgar/data/1173738/000121465906001841/0001214659-06-001841.txt
NEWS! 3 units sold!!!!!
Press Release Source: CDEX, Inc.
Texas Children's Hospital Selects ValiMed(TM) Medication Validation System for Hospital Pharmacy
Tuesday August 15, 11:00 am ET
Three ValiMed Units Purchased to Verify Compounded Medication Doses, and Validate Narcotic Returns
ROCKVILLE, Md.--(BUSINESS WIRE)--Aug. 15, 2006--CDEX Inc. (OTCBB:CEXI - News) announced today that Texas Children's Hospital has purchased three ValiMed systems to perform end product testing of compounded intravenous medications in its pharmacy departments, and validation of returned narcotics in its operating room suites and nursing units. The ValiMed Medication Validation System, developed by CDEX and distributed exclusively by Baxa Corporation, provides clinicians with a quick, cost effective, and simple tool to further ensure medication safety by verifying medications are correctly compounded. Texas Children's Hospital is an internationally recognized full-care pediatric hospital located in the Texas Medical Center in Houston. One of the largest pediatric hospitals in the United States, Texas Children's Hospital is dedicated to providing the finest possible pediatric patient care, education, and research.
In a process that takes only seconds, ValiMed uses patent pending technology to validate compounded doses of high-risk medications prior to dispensing to the patient care area. The solution creates an added level of safety in the medication dispensing process, and is also used to validate narcotic returns as well as identify counterfeit medications.
"The Pharmacy Leadership at Texas Children's Hospital continues to look for opportunities to enhance our safety strategies. Since the majority of our medications are compounded, the ValiMed technology will provide an additional layer of safety and enable us to verify accuracy of multiple doses in a more timely fashion," said Karen Gurwitch, Director of Pharmacy at Texas Children's.
"We feel privileged to add Texas Children's Hospital to our growing list of internationally recognized healthcare organizations that are using ValiMed," said Jim Griffin, President and CEO of CDEX Inc. "Texas Children's recognizes the value of ValiMed and has purchased multiple ValiMed units for use across their hospital pharmacy compounding, medication dispensing, and return verification processes."
ValiMed validates medications to ensure that the correct drugs, in the correct amounts, in the correct diluent have been added to the dose during the compounding process. The ValiMed Medication Validation System is distributed under an exclusive agreement with Baxa Corporation (www.baxa.com) of Englewood, Colorado.
About Texas Children's Hospital
Established in 1954 and located in the heart of the Texas Medical Center in Houston, Texas Children's Hospital is committed to providing the finest possible patient care, education and research. The nonprofit hospital is ranked among the top five pediatric hospitals nationwide by both U.S. News and World Report and Child. For more information, visit the website at www.texaschildrenshospital.org.
About Baxa Corporation
Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for fluid handling and delivery. Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of fluid medications. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada and the United Kingdom; direct representation in Belgium, Denmark, Finland, France, Germany, Luxembourg and The Netherlands; and distribution partners worldwide. Further information is available at www.baxa.com.
About CDEX Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market; and (ii) identification of substances of concern (e.g., illegal drugs for law enforcement in the homeland security market) CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com.
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.
Contact:
CDEX, Inc.
Jerry Blair, 301-881-0080
jblair@cdex-inc.com
Source: CDEX, Inc.
thanks Charlie. i am aware of the raging Bull posts.
I was just seeking an alternative IHub board that is not polluted with 5 year old BS,and non shareholders.
Try this site:
http://ragingbull.lycos.com/mboard/viewclub.cgi?board=CLB01212
Lots of knowledgeable posters with a minimum of bashing.
Cheers, Charlie
I do not understand why this board is being allowed to dry up.
Did I miss something somewhere?
Is it a case of the only way some investors can be motivated is to read and post on boards full of BS rebuttles to any news and suggestions from people that have one interest only.
TO SINK Cdex
We post on an Investors hub Loch Harris board stating that Loch harris is Cdex. As far as I'm concerned nothing is further from the truth.Loch Harris died 5 years ago,in spite of their insistance that the same people are running it
The other Invstors hub Cdex board is now dominated by people rebutting anything that is presented,
This is a ValiMed board. I wasn't aware of the fact that the ValiMed system is so secure it does not require discussion. that newer PR's are not of interest.
Maybe just maybe I missed the boat. Like if we don't discuss ValiMed here the bashers will not pick on us LOL.
New ValiMed(TM) Medication Validation System DemonstratesUSP < 797 > Compliance at ASHP Summer Meeting Baxa Corporation demonstrates the next-generation ValiMed System for medication safety at booth no. 729 at the American Society of Health-System Ph
ENGLEWOOD, Colo., June 26, 2006 /PRNewswire via COMTEX/ -- Baxa Corporation
announces the release of the next-generation ValiMed Medication Validation
System at the summer meeting of the American Society for Health-System
Pharmacists. The ValiMed System validates medications and concentrations;
allowing users to detect counterfeit products for brand protection, provide
quality assurance for compounded products, and detect narcotic loss. The ValiMed
System ensures patient safety in real time, by verifying that medications are
correctly compounded.
ValiMed features patent-pending technology that validates in seconds the
strength of compounded doses of high risk medications prior to dispensing.
Verification of compounding accuracy and sterilization is a requirement under
USP 27-NF 22 Chapter < 797 >, which regulates the compounding of sterile
products. The ValiMed System can play a key role in demonstrating the safety of
compounded sterile products (CSPs) under these requirements.
The updated version of the ValiMed System -- shown for the first time at the
ASHP meeting -- incorporates reports used to comply with USP 797 requirements.
It also features a modified disposable, requiring a reduced sample volume for
testing. "This next-generation ValiMed System addresses customer requests,"
notes Product Manager Mark Thrasher. "It's more robust and the smaller sample
requirement more easily accommodates current pharmacy work flows."
During the meeting, Baxa representatives will demonstrate the ValiMed System's
capabilities in their booth, number 729. Pharmacists will see first-hand how the
system ensures the accuracy of their compounded solutions and helps them meet
both USP 797 verification and JCAHO requirements for patient safety.
About Baxa Corporation
Baxa, a customer-focused medical device company, provides innovative,
solution-based technologies for fluid handling and delivery. Its systems and
devices promote the safe and efficient preparation, handling, packaging, and
administration of fluid medications. Privately held, Baxa Corporation has
subsidiaries and sales offices in Canada and the United Kingdom; direct
representation in Belgium, Denmark, Finland, France, Germany, Luxembourg and The
Netherlands; and distribution partners worldwide. Further information is
available at www.baxa.com.
About CDEX, Inc.
CDEX Inc. (OTC Bulletin Board: CEXI), the manufacturer of the ValiMed System, is
a technology development company focused on producing equipment that uses using
chemical detection and validation technologies. CDEX technology is focused
currently on two distinct areas: (i) identification of substances of concern
(e.g., explosives and illegal drugs); and (ii) validation of substances for
anti-counterfeiting, brand protection and quality assurance. CDEX is
headquartered in Rockville, Maryland, with a primary research and development
laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and
www.valimed.com.
CDEX Second Quarter Revenue Highest in Company's History; ValiMed Leads the Way
ROCKVILLE, Md., Jun 16, 2006 (BUSINESS WIRE) -- CDEX, Inc. (OTCBB:CEXI.OB)
announced today that it recorded the highest quarterly revenue in the history of
the company in the fiscal second quarter, ending April 30, 2006. Revenue was
$351,038 as compared to $23,860 during the second fiscal quarter of 2005. The
increase of $327,177 (or 1,371%) resulted from the delivery of ValiMed (TM)
medication verification systems to Baxa Corporation. Baxa represents the CDEX
ValiMed product line, exclusively in the USA and Canada.
During the period from January 2006 through April 2006, CDEX successfully
managed its production plan for the ValiMed medication verification system, that
included, but was not limited to the following: completing the ValiMed design
package; developing a new proprietary cuvette; identifying, qualifying, and
setting up contract manufacturers for ValiMed and the new proprietary cuvette;
developing new medications and drugs signatures for the ValiMed production
units, completing product certification testing and obtaining the TUV mark, and
delivering the first production units to Baxa on-time and on-budget.
"The shareholders, management, and staff of CDEX take great pride in what has
been accomplished. This achievement represents the culmination of several years
of research and development, determination, and perseverance by a lot of very
dedicated people to bring ValiMed to market. We are proud of what we have
achieved, and awed by the opportunities that are before us. The introduction of
ValiMed into the hospital pharmacy market is a significant contribution to
society. The ValiMed medication verification system gives clinicians and
healthcare professionals a quick, cost effective, and simple tool to further
ensure medication safety by verifying that medications are correctly compounded.
ValiMed can make a difference to hospital patients by preventing injuries and
the loss of life due to medication errors," said Jim Griffin, President and CEO
of CDEX, Inc.
About CDEX Inc.
CDEX Inc. is a technology development company with a current focus on developing
and marketing products using chemical detection and validation technologies. At
present, CDEX is devoting its resources to two distinct areas: (i) and quality
assurance (e.g., validation of prescription medication and detection of
counterfeit or sub-par products for brand protection). ValiMed is one line of
CDEX products for the healthcare market; and (ii) identification of substances
of concern (e.g., illegal drugs for law enforcement in the homeland security
market) CDEX is headquartered in Rockville, Maryland with its research and
development laboratory in Tucson, Arizona. For more information, visit
www.cdex-inc.com.
Any statements made in this press release which contain information that is not
historical are essentially forward-looking. Many forward-looking statements can
be identified by the use of words such as "expects," "plans," "may,"
"anticipates," "believes," "should," "intends," "estimates," and other words of
similar meaning. These statements are subject to risks and uncertainties that
cannot be predicted or quantified and, consequently, actual results may differ
materially from those expressed or implied by such forward-looking statements.
Such risks are detailed from time-to-time in filings with the Securities and
Exchange Commission. There is no obligation to publicly update any
forward-looking statements.
SOURCE: CDEX, Inc.
CONTACT: CDEX, Inc.
Jerry Blair, 301-881-0080
jblair@cdex-inc.com
Here is the Town Meeting that (I guess) we must have been at...
http://www.fda.gov/OHRMS/DOCKETS/98fr/020602e.htm
Agenda: On February 25, 2002, the subcommittee will:
(1) Identify and define technology and regulatory uncertainties/hurdles, possible solutions, and strategies for the successful implementation of process
analytical technologies (PATs) in pharmaceutical development and manufacturing;
(2) discuss general principles for regulatory
application of PATs including principles of method validation, specifications, use and validation of chemometric tools, and feasibility of parametric release concept; and
(3) discuss the need for
a general FDA guidance to facilitate the implementation of PATs.
On February 26, 2002, the subcommittee will discuss strategies to explore issues in the following four focus areas:
(1) Product and process development,
(2) process and analytical validation,
(3) chemometrics, and
(4) process analytical technologies, applications and
benefits.
***************************************
Here is the overview of the Feb meeting
http://www.fda.gov/ohrms/dockets/ac/cder02.htm#PharmaceuticalScience
Here is one of the Presenters that we mentioned in our response back to ASD...AstraZeneca...
http://www.fda.gov/ohrms/dockets/ac/02/slides/3841s1_06_chisholm.ppt#264,5,SolidDosageFacility
....If you hang on long enough the NIR will show up at all of the green boxes or stages of development except the last one where they coat the pill...
**********************
Oh yeah...here is the real "key"....Just thought you may want to see for yourself..scroll down..
Working Group 1...
take a look Mr. Curtiss was there... big as you Please....
http://www.fda.gov/ohrms/dockets/ac/02/roster/3841r1_02_workinggroup1.htm
Fourth Affirmative Defense In-Equitable Conduct.
(Thank You Pookie)
The 369 patent is un-enforceable as a result of inequitable conduct arising from plaintiffs and or plaintiffs councils intentional failure to disclose relevant prior art that was material to the patentability of the claims of the 369 patent.
Plaintiff was specifically aware of prior art including prior invention material to the patentability of the claims of the 369 patent before and during prosecution of the 369 patent.
Nevertheless upon information and belief plaintiff intentionally failed to disclose such material prior art to the us patent and trademark office USPTO thereby committing fraud on the uspto.
More specifically one of the inventors of the 369 patent Mr. Brian Curtis attended and FDA advisory board meeting for the process of Analytical Technologies subcommittee of the Advisory Committee for the Pharmaceutical Science held February 25 and 26 Curtis
Mr. Curtiss was an official industry guest participant of the FDA Advisory Committee for Pharmaceutical Science and was designated as a member of the Process Analytical Technology (PAT) Subcommittee working Group.
In such capacity he received testimony on Near Infra red NIR applications in pharmacy practice.
During the meetings among others things Pfizer Cooperation made a presentation entitled and industry perspective on the potential for "Emerging Process Analytical Technologies"
The presentation among other things included a detailed discussion of the use of NIR or pharmaceutical compounds.
In particular one of the presentation slides was entitled NIR Tablet Transmission Device.
This slide illustrated how the composition of a tablet may be analyzed using a NIR spectrum
Another presentation entitled Total Quality Management System (TQMS) was presented by AstraZeneca during the February 26 and 26 meetings.
The presentation also included a detailed discussion of the use of NIR analysis of pharmaceutical compounds.
Slides of this presentation show among other things a TQMS analyzer capable of analyzing tablets.
Plaintiff plaintiffs councils and Mr.,. Curtis all failed to disclosed the existence of this Prior Art which is material to the patentability of the claims of the 369 patent to the USPTO during prosecution of the 369 patent. In fact shortly after the FDA Advisory Board Meeting, Plaintiff rushed to the USPTO to file its alleged "own" patent application ) (The application for the 369 Patent) and did not inform the USPTO of for example, the Pfizer and the Astra Zeneca presentations.
Moreover, Upon information and belief no Pfizer or Astra Zeneca presentations upon information and Believe no Pfizer or Astra Zeneca individuals were named as inventors on the 369 patent. To the extent that incorrect inventors have been identified with the intent to deceiver the USPTO such would constitute fraud by Plaintiff on the USPTO...
Paige there is also another CDEX board here.
http://www.investorshub.com/boards/board.asp?board_id=2560
and here on CBS
http://www.marketwatch.com/discussions/msgIndex.asp?siteId=mktw&parentId=2&forumId=7&boa....
and here of Free Real Time
http://quotes.freerealtime.com/rt/frt/M?SA=quotes|MessageBoard&IM=quotes&symbol=CEXI&typ....
and here on Stock Selector
http://boards.stockselector.com/board.asp?symbol=CEXI
Sassy...I didn't know we had a Valimed Board..
That is great!..I will mark it..
This morning I Played back both of our Web Tv Spots...and thought to my self..boy we sure have come a loong loong way..
To just now... be at the very start..
We have defied the odds..that's for sure..
With each firmly planned step taken forward by this company..
The types of websites..we are showing and linking our Valimed on are top quality..
As well as the types of websites we aren't on...
hint: (pennystock)
We have placed ourselves amongst the highest...the Decision Makers..the Regulators...
...and we will make a difference in our world..
CDEX, Inc. Delivers First Production ValiMed Medication Validation System
ROCKVILLE, MD.–April 25, 2006– CDEX, Inc. (CEXI.OB) announced today that it has delivered the first ValiMed Medication Validation System production units in the initial installment of the systems purchased by Baxa Corporation (www.baxa.com) under their reseller agreement with CDEX (www.cdex-inc.com). The ValiMed Medication Validation System is designed to verify narcotic disposal and validate pharmaceuticals, including concentration and diluents, in patient medications. The first production units were prepared to verify 33 medications (nine narcotics and 24 medications) for both doses and diluents.
The information obtained from CDEX beta partners has permitted the company to incorporate significant changes to the system from the original design. The current configuration can validate narcotic disposal of such narcotics as Fentanyl at 50 mcg/ml and differentiate patient care drugs such as Epinephrine at 0.005 mg/ml and Epinephrine at 0.01 mg/ml.
“The delivery of the first ValiMed production units marks a significant milestone in the CDEX growth strategy. The shipment of the ValiMed systems has positioned the company to focus on overall market penetration for the ValiMed product. Our proven production capabilities coupled with our recent TUV certification has opened significant opportunities for us both in the U.S. and overseas,” stated Jim Griffin, President and CEO of CDEX, Inc.
The ValiMed medication library currently consists of 33 narcotics and patient care medications, and is scheduled to be expanded to more than 140 medications, doses and diluents, by the end of the year. ValiMed’s improved capabilities and an expanding medication library will ensure that the system becomes an essential tool for improving patient safety.
About CDEX, Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com.
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the ability of the Company to raise capital to finance the development of its chemical detection products, the effectiveness, profitability and the marketability of those products, the ability of the Company to protect its proprietary information, the establishment of an efficient corporate operating structure as the Company grows and, other risks detailed from time-to-time in our filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statements.
Media Contact:
Brad Wills
Wills & Associates, Inc.
t. 301-767-1919
m. 301-346-7398
bwills@wills-pr.com
ValiMed Receives Clean Bill of Health from TUV Rheinland of North America, Inc.
Monday April 10, 11:22 am ET
CDEX is Authorized to use TUV Mark on ValiMed
ROCKVILLE, Md.--(BUSINESS WIRE)--April 10, 2006--CDEX, Inc. (CEXI.OB) announced today that it received permission from TUV Rheinland of North America Inc. (www.us.tuv.com) to apply the TUV mark to the ValiMed(TM) 1.0 system after completing an exhaustive three month product certification testing and quality assurance inspection of the manufacturing processes. The ValiMed medication verification system, which was developed by CDEX (www.cdex-inc.com) and is exclusively distributed by Baxa (www.baxa.com), gives clinicians a quick, cost effective, and simple tool to further ensure medication safety by verifying that medications are correctly compounded.
More here...
http://biz.yahoo.com/bw/060410/20060410005699.html?.v=1
One step closer folks!
Cheers, Charlie
Children's Hospitals and Clinics of Minnesota Selects CDEX ValiMed(TM) to Implement Medication Validation Solution
Monday April 3, 7:55 am ET
ValiMed System Verifies Compounded Medications and Doses, and Validates Narcotic Returns
ROCKVILLE, Md. & MINNEAPOLIS--(BUSINESS WIRE)--April 3, 2006--CDEX, Inc. (OTCBB:CEXI - News), announced today that Children's Hospitals and Clinics of Minnesota has selected the ValiMed(TM) system to perform end-product testing of compounded intravenous medications in its pharmacy departments, and validation of returned narcotics in its operating room suites and nursing units. The ValiMed medication verification system, which was developed by CDEX (www.cdex-inc.com) and is exclusively distributed by Baxa (www.baxa.com), gives clinicians a quick, cost effective, and simple tool to further ensure medication safety by verifying medications are correctly compounded.
ADVERTISEMENT
Children's of Minnesota is the eighth-largest children's health care organization in the U.S., with 319 staffed beds at its two hospital campuses in St. Paul and Minneapolis, Minnesota. An independent, not-for-profit health care system, Children's of Minnesota provides care through over 13,000 inpatient visits and more than 200,000 emergency room and other outpatient visits each year.
In a process that takes only seconds, ValiMed uses patent pending technology to validate compounded doses of high-risk medications prior to dispensing. The solution creates an added level of safety in the medication dispensing process, and is also used to validate narcotic returns as well as identify counterfeit medications.
"At Children's, our top priority is the safety of our patients. With the ValiMed product we will enhance our patient and medication safety by verifying compounded medication and narcotic returns right in the pharmacy," said Christine Koentopp, Director of Pharmacy at Children's Hospitals and Clinics of Minnesota.
"We are pleased that Children's of Minnesota has joined a list of nationally recognized healthcare organizations that have adopted this new health safety measure, and is the first healthcare system in Minnesota to use ValiMed," said Jim Griffin, CEO for CDEX. "It is gratifying to see ValiMed being accepted as a life safety and quality control product by healthcare professionals across the nation. The number of prestigious healthcare organizations that are adopting ValiMed to verify compounded medications and doses, and validate narcotic returns continues to grow."
The ValiMed solution uses light energy and a library of unique spectral fingerprints to validate drugs in solution. The device validates that the correct drugs in the correct amounts have been added to the dose during the compounding process. The ValiMed Medication Validation System is distributed under an exclusive agreement with Baxa Corporation (www.baxa.com) of Englewood, Colorado.
About Children's Hospitals and Clinics of Minnesota
Children's of Minnesota has received national recognition for its work in patient safety, including a recent ranking as one of only eight pediatric hospitals among the "50 Exceptional U.S. Hospitals" by the Leapfrog Group, a consortium of 165 national employers that provide health coverage to 36 million employees. For more information about Children's of Minnesota, visit www.childrensmn.org.
About CDEX, Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com.
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.
Contact:
For CDEX, Inc.
Wills & Associates
Brad Wills, 301-767-1919
bwills@wills-pr.com
--------------------------------------------------------------------------------
Source: CDEX, Inc.
Baxa to Feature ValiMed Medication Validation System at Interphex 2006
http://www.prweb.com/releases/2006/3/prweb360447.htm
Baxa Corporation features the innovative ValiMed System technology for rapid validation of high-risk medications at the Interphex 2006 trade show March 20-23, 2006, at Booth # C302. This new system provides the only effective means for preventing med errors, detecting narcotic abuse and ensuring the quality of batch compounds.
Englewood, Colo. March 20, 2006 – Baxa Corporation will feature its new ValiMed Medication Validation System at the upcoming Interphex meeting at the Jacob Javits Convention Center in New York City (http://interphex.com). Over the course of the three-day meeting, Baxa representatives will demonstrate how this unique technology prevents medication errors by validating drugs and concentrations, detecting counterfeit products for brand protection, and providing quality assurance for compounded products. The ValiMed System also is used for prevention and detection of narcotic diversion.
The ValiMed System provides clinicians a simple, cost-effective tool for ensuring medication safety. Its patent-pending technology identifies drug strength in real time, validating compounded doses of high-risk medications prior to dispensing. “The ValiMed Solution fits with Baxa Corporation's mission to improve pharmacy operations and increase the safety of admixture and administration activities,” notes Product Manager Mark Thrasher. “ValiMed complements our existing automation, admixture and drug delivery products well.”
According to the National Institute on Drug Abuse (NIDA), between 8% and 12% of healthcare workers have chemical dependencies. Healthcare professionals may be at increased risk of prescription drug abuse because of their easy access to medications, including controlled substances. Using the ValiMed Technology, pharmacy directors and other managers can detect narcotic loss and prevent on-the-job impairment, which can compromise patient care.
Pharmacists and other healthcare professionals continue to explore new uses for the medication validation offered by the ValiMed System. The system has applications for clinical trial validation and quality control, as well. The future of healthcare safety will be demonstrated at booth no. C302 during the Interphex exhibit hours.
For more than 30 years, Baxa Corporation has focused on developing systems and devices that streamline pharmacy operations, enhancing patient safety and improving efficiency. Under an agreement announced in early November, Baxa is the exclusive distributor of the CDEX ValiMed System for healthcare organizations in the United States and Canada.
About Baxa Corporation
Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for fluid handling and delivery. Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of fluid medications. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada and the United Kingdom; sales infrastructure in Belgium, Denmark, Finland, France, Germany, Luxembourg and the Netherlands; and distribution partners worldwide. Further information is available at http://www.baxa.com.
About CDEX, Inc.
CDEX Inc. (OTCBB: CEXI), is a technology development company focused on products using chemical detection and validation technologies. CDEX technology currently covers two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance. CDEX is headquartered in Rockville, Maryland, with a primary research and development laboratory in Tucson, Arizona. For more information, visit http://www.cdex-inc.com.
Additional information about the new ValiMed™ Medication Validation System and medication errors may be found at http://publicrelationsnewsroom.com/_wsn/page15.html.
Contacts:
Marian Robinson, Vice President, Marketing
Baxa Corporation http://www.baxa.com: 800.567.2292 ext. 2157 or 303.617.2157
Maggie Chamberlin Holben, APR
Absolutely Public Relations http://www.absolutelypr.com: 303.984.9801 or 303.669.3558
News for 'CEXI' - (Henry Ford Hospital Selects ValiMed From CDEX For Medication Validation; ValiMed Verifies Compounded Medications and Doses and Validates Narcotic Returns)
ROCKVILLE, Md. & DETROIT, Mar 16, 2006 (BUSINESS WIRE) -- Henry Ford Hospital
has selected the ValiMed system to perform end-product testing of compounded
intravenous medications in its pharmacy departments, and validation of returned
narcotics in its operating room suites and nursing units. The ValiMed medication
verification system was developed by CDEX (CEXI.OB) to give clinicians a quick,
cost effective, and simple tool to further ensure medication safety by verifying
medications are correctly compounded.
Henry Ford is a 903-bed tertiary care hospital, education and research complex
in Detroit. The hospital is recognized for clinical excellence and innovations
in the fields of cardiology and cardiovascular surgery, neurology and
neurosurgery, orthopaedics and rehabilitation, organ transplantation, and
treatment for prostate, breast and lung cancers, among others. Its Emergency
Department is a Level 1 trauma center. Henry Ford is the flagship hospital for
Henry Ford Health System, whose mission is to improve human life through
excellence in the science and art of health care and healing.
In a process that takes only seconds, ValiMed uses patent-pending technology to
validate compounded doses of high-risk medications prior to dispensing. The
solution creates an added level of safety in the medication dispensing process,
and is also used to validate narcotic returns as well as identify counterfeit
medications.
"At Henry Ford, our top priority is patient safety. The ValiMed product
strengthens our dispensing process by adding another level of safety to ensure
compounded medications are accurately verified and narcotic returns are properly
handled in the pharmacy," said Ed Szandzik, Director of Pharmacy at Henry Ford
Hospital.
"We are pleased to be working with Henry Ford Hospital, yet another nationally
recognized healthcare organization that has chosen to deploy ValiMed," said Jim
Griffin, CEO for CDEX. "Partners like Henry Ford are valuable as CDEX continues
its strategic growth in the healthcare sector."
The ValiMed by CDEX solution uses light energy and a library of unique spectral
fingerprints to validate drugs in solution. The device validates that the
correct drugs in the correct amounts have been added to the dose during the
compounding process.
About CDEX, Inc.
CDEX Inc. is a technology development company with a current focus on developing
and marketing products using chemical detection and validation technologies. At
present, CDEX is devoting its resources to two distinct areas: (i)
identification of substances of concern (e.g., explosives and illegal drugs for
homeland security); and (ii) validation of substances for anti-counterfeiting,
brand protection and quality assurance (e.g., validation of prescription
medication and detection of counterfeit or sub-par products for brand
protection). ValiMed is one line of CDEX products for the healthcare market.
CDEX is headquartered in Rockville, Maryland with its research and development
laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and
www.valimed.com.
Any statements made in this press release which contain information that is not
historical are essentially forward-looking. Many forward-looking statements can
be identified by the use of words such as "expects," "plans," "may,"
"anticipates," "believes," "should," "intends," "estimates," and other words of
similar meaning. These statements are subject to risks and uncertainties that
cannot be predicted or quantified and, consequently, actual results may differ
materially from those expressed or implied by such forward-looking statements.
Such risks are detailed from time-to-time in filings with the Securities and
Exchange Commission. There is no obligation to publicly update any
forward-looking statements.
SOURCE: CDEX Inc.
CONTACT: CDEX, Inc.byWills & AssociatesBrad Wills, 301-767-1919bwills@wills-pr.com
Copyright Business Wire 2006
-0-
KEYWORD: United States
North America
Maryland
Michigan
INDUSTRY KEYWORD: Technology
Hardware
Software
Health
Biotechnology
Hospitals
Medical Devices
Pharmaceutical
Professional Services
Insurance
Legal
SUBJECT CODE: Contract/Agreement
Product/Service
All Children’s Hospital Selects ValiMed™ System for
Medication Validation
Developed by CDEX, the ValiMed System was chosen by All Children’s to Verify Compounded Medications and Doses, and Validate Narcotic Returns
ROCKVILLE, MD-- March 14, 2006 – CDEX Inc., announced today that All Children’s Hospital in St. Petersburg, Florida has selected the ValiMed Medication Validation System to perform end-product testing of compounded intravenous medications in its pharmacy departments, and validation of returned narcotics in its operating room suites and nursing units. The ValiMed System, developed by CDEX (CEXI.OB), gives clinicians a quick, cost- effective, and simple tool to ensure medication safety by verifying medications are correctly compounded. All Children’s Hospital, a 216-bed teaching hospital affiliated with the University of South Florida College of Medicine, is a leading center for pediatric treatment, education, and research.
In a process that takes only seconds, the ValiMed System uses patent-pending technology to validate compounded doses of high-risk medications prior to dispensing. The system documents the accuracy of the medication dispensing process, and is used to validate narcotic returns as well as identify counterfeit medications.
"We are pleased that a nationally recognized institution, such as All Children’s Hospital of Florida, is now using our ValiMed System for medication validation,” said Jim Griffin, President and CEO of CDEX.
The ValiMed System uses light energy and a library of unique spectral fingerprints to validate drugs in a solution. The device validates that the correct drugs in the correct amounts have been added to the dose during the compounding process. The ValiMed Medication Validation System is distributed under an exclusive agreement with Baxa Corporation of Englewood, Colorado.
About CDEX, Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com.
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the ability of the Company to raise capital to finance the development of its chemical detection products, the effectiveness, profitability and the marketability of those products, the ability of the Company to protect its proprietary information, the establishment of an efficient corporate operating structure as the Company grows and, other risks detailed from time-to-time in our filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statements.
Media Contact:
Brad Wills
Wills & Associates, Inc.
t. 301-767-1919
m. 301-346-7398
bwills@wills-pr.com
Most of the selling was toward the end of the year, could be for tax reasons.I asked a broker this,If a company share price were expected to rise, why would they sell any shares at at lower rate, He said that is a smart move, gave me this link, this may give you some insight. http://cs.smartmoney.com/tax/capital/index.cfm?story=amtiso
CDEX Announces Annual Shareholders Meeting
Last Update: 8:45 AM ET Mar 2, 2006
ROCKVILLE, Md., Mar 02, 2006 (BUSINESS WIRE) -- CDEX, Inc. (CEXI.OB), a developer of innovative technologies for detecting and validating chemical substances, announced today that its 2006 annual meeting of shareholders will be held on Friday, March 17, 2006, at 10:00 a.m. ET at the Doubletree Hotel, 1750 Rockville Pike, Rockville, MD, 20852 / telephone: 301-468-1100.
Proxy statements and proxy cards were mailed out on February 17, 2006. Proxies are to be returned to the address shown on the proxy card by no later than 11:59 p.m., March 16, 2006.
About CDEX, Inc.
CDEX, Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com.
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the ability of the Company to raise capital to finance the development of its chemical detection products, the effectiveness, profitability and the marketability of those products, the ability of the Company to protect its proprietary information, the establishment of an efficient corporate operating structure as the Company grows and, other risks detailed from time-to-time in our filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statements.
SOURCE: CDEX, Inc.
For CDEX Brad Wills, 301-767-1919 bwills@wills-pr.com Copyright Business Wire 2006
NEW CDEX PR Expands its Business to Include the Security Market
Monday February 27, 2:47 pm ET
CDEX, Inc. taps Charles C. Foster to serve as new Director of Business Development for Homeland Security
ROCKVILLE, Md.--(BUSINESS WIRE)--Feb. 27, 2006--CDEX, Inc. (CEXI.OB), a developer of innovative technologies for detecting and validating chemical substances, announced that Charles C. Foster has been appointed to the position of Director of Business Development, Homeland Security. Mr. Foster comes to CDEX from a background in law enforcement, sales and business development for security technologies.
At CDEX, Mr. Foster will be responsible for building the company's sales channels by developing a network of strategic partners consisting of; prime government contractors and lead system integrators, and resellers for the company's Homeland Security and commercial security business. The core technologies developed by CDEX for chemical substance detection and identification have numerous applications for law enforcement and defense, including illicit drug and explosive materials detection, as well as anti-counterfeiting solutions for brand safety and consumer protection.
"CDEX is very pleased to welcome Chuck Foster on board," said Mr. James Griffin, President & CEO of CDEX, Inc. "His experience in public safety and security technologies will be invaluable to CDEX as it seeks to expands its business into the Homeland Security and commercial security sectors. Mr. Foster's addition to the CDEX management team is an important step in the furtherance of our growth strategy for CDEX."
Mr. Foster has had a nearly 30-year career in law enforcement, sales, and security technologies business development. Mr. Foster began his career as a police officer for New Castle County, Delaware, before entering the private sector in 1983 to pursue business development initiatives for a range of technology and security businesses, including ADT, Controlled Access, Maris Equipment, and Infographic Systems. Prior to joining CDEX, Mr. Foster was Technical Relationship Manager for Cernium, Inc., the developer of intelligent video analytics systems. There he helped to establish the company's market-leading position within video security, grow direct sales, and develop strategic relationships with integrators, VARs, and partnering businesses.
About CDEX, Inc.
CDEX, Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com.
Contact:
CDEX, Inc., Rockville
Media:
Brad Wills, 301-767-1919
bwills@wills-pr.com
--------------------------------------------------------------------------------
Source: CDEX, Inc.
Cdex targets $1B market for stopping fake drugs
http://www.bizjournals.com/washington/stories/2006/02/20/story4.html?from_rss=1
Neil Adler
Staff Reporter
Cdex, a Rockville business working on technology that detects chemicals, is about to go from developing a product to selling it. And that could mean big revenue and a larger staff for the small company seeking a piece of a $500 million to $1 billion market.
Recent Company News
» Baxa
» Maryland Pharmacists Association
» University of Maryland Medical Center
Latest News
» Fairfax County sees big increase in venture capital funding
» Private space flights given lift by Arlington company
» New economic development chief tapped in Anne Arundel
» New Maryland Web site helps startups seeking funds
» Tech firm GTSI names new CEO
More
» Companies in the News
» People in the News
» Get the latest business news on the go!
Brought to you by Cingular
With the first production run of its ValiMed system slated for April, Cdex expects to generate about $50 million in annual revenue in three years and $100 million by 2011.
The company (www.cdex-inc.com) has begun to sign up customers, including the University of Maryland Medical Center in Baltimore, for its chemical-detection system that helps medical professionals determine whether the drugs they receive are counterfeit.
"It's a big issue," says Howard Schiff, executive director of the Maryland Pharmacists Association. "Counterfeiting techniques are becoming more refined. It is very difficult to tell if [a drug] is counterfeit."
Cdex's technology uses X-rays and ultraviolet light -- as well as hardware and software -- to identify substances and weed out false positives, which happen frequently during attempts to detect hazardous materials. Customers are likely to pay about $25,000 for each ValiMed system.
"We're unaware of a competitor that is offering a similar product," says Jim Griffin, who joined Cdex Oct. 1 as chief operating officer and was named president and CEO Jan. 1. He replaced Malcolm Philips, who started the company in 2001.
"We believe what we have is exciting," says Griffin, who has also been named to Cdex's board.
The University of Maryland Medical Center will use ValiMed to perform end-product testing of intravenous medications in its pharmacy departments and to validate returned narcotics in operating rooms and nursing units. University officials say they are integrating the technology but preferred not to comment because they're just learning how to use the system.
The company has 17 employees between its Rockville headquarters and a facility for research and development in Tucson, Ariz. Griffin says he plans to at least double -- and perhaps triple -- the company's staff in the next 12 to 18 months. The new workers will be needed for sales, marketing and R&D.
Cdex, which is traded over the counter, plans to raise $3.5 million to $10 million this year for product development, although company executives won't say how the money will be secured. Cdex raised $3.6 million last year.
The company reported a net loss of
$5.2 million on revenue of $178,000 for fiscal 2005 ended Oct. 31, compared with a net loss of $5.9 million on revenue of roughly $4,000 a year earlier.
Cdex recently signed an agreement with Englewood, Colo.-based Baxa to sell its product line in the United States and Canada and is looking for partners to market the technology overseas.
The firm's technology targets health care but could be applied to the homeland security and brand protection markets, Griffin says. Defense officials, for example, could use it to screen for explosives and illegal drugs, and liquor industry leaders could use it to ensure the spirits they've ordered are legit.
Says Griffin: "Our opportunities are broad and vast."
E-mail: Nadler@bizjournals.com Phone: 703/816-0332
Another New Press Release.....
http://www.cdex-inc.com/pr/21606b.html
PRESS RELEASE
BWX Technologies Names CDEX Director George Dials President and General Manager of the NNSA Y-12 National Security Complex in Oak Ridge, TN
ROCKVILLE, MD – FEBRUARY 16, 2006 – CDEX, Inc. (CEXI.OB) announces that Mr. George E. Dials, a CDEX Director since 2001, has been named President and General Manager of the National Nuclear Security Administration’s (NNSA) Y-12 National Security Complex in Oak Ridge, Tennessee operated by BWX Technologies (BWXT). Mr. Dials assumes responsibility effective February 20, 2006, and will continue his work with the CDEX Board.
In a February 6, news release, BWXT President and COO Mr. John A. Fees commented on the appointment: “George brings the experience necessary to manage and operate this nuclear weapons complex. For more than five years, BWXT has had a positive influence on Y-12’s operations. With George as part of our management team, it is a testament to our unyielding commitment to the Y-12 facility, employees and the DOE.”
Mr. Dials has spent nearly 30 years in the energy and nuclear industries, most recently serving as president and COO of a private hazardous waste disposal facility. Previously, he served as the president and general manager for TRW Environmental Safety Systems management and operations of the Yucca Mountain Project. His career has also included leadership positions with ICF Kaiser International, and the Department of Energy’s Carlsbad and Idaho Falls Offices. Mr. Dials entered the nuclear and energy industries after a ten-year career in the U.S. Army, where he served as an airborne ranger infantry officer in Germany, Vietnam, and Korea. Mr. Dials earned a Silver Star and Bronze Star for Valor in combat operations in Vietnam. As an Army nuclear weapons specialist, he was assigned to the Los Alamos National Laboratory for research on Army nuclear weapons planning and development. Mr. Dials holds an M.S. in nuclear engineering and an M.S. in political science from the Massachusetts Institute of Technology, and a B.S. in engineering from the United States Military Academy, West Point, New York.
BWXT, headquartered in Lynchburg, VA, has a long history in nuclear manufacturing and operations, both in the DOE and at its unique, highly secure, privately owned and operated nuclear manufacturing and laboratory facilities. Supplying the U.S. government and commercial clients with nuclear products and services for over 50 years, BWXT has unparalleled experience in nuclear safeguards and security. BWXT is responsible for the operations of the DOE’s National Nuclear Security Administration’s Pantex Plant in Texas and Y-12 National Security Complex in Tennessee, along with nuclear operations at the Idaho National Laboratory. BWXT has more than 11,300 employees in 11 states and is a subsidiary of McDermott International, Inc. (NYSE: MDR).
About CDEX, Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit
www.cdex-inc.com.
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the ability of the Company to raise capital to finance the development of its chemical detection products, the effectiveness, profitability and the marketability of those products, the ability of the Company to protect its proprietary information, the establishment of an efficient corporate operating structure as the Company grows and, other risks detailed from time-to-time in our filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statements.
PRESS RELEASE..CDEX Enhances Protection of Intellectual Property Around Substance Detection and Validation Technologies
Thursday February 16, 4:15 pm ET
ROCKVILLE, Md.--(BUSINESS WIRE)--Feb. 16, 2006--CDEX, Inc. (OTCBB:CEXI.OB - News), a developer of innovative technologies for detecting and validating chemical substances, received a notification of allowance from the U.S. Patent and Trademark Office for Patent Application Publication Number 20030128804, entitled "System and Method for Adapting a Software Control in an Operating Environment." The patent applies to a system and method developed by CDEX for detecting substances--such as explosives or controlled substances. The technology exposes target substances to an x-ray energy beam and then analyzes and compares the released fluorescent energy to a database of unique energy signatures of known substances. CDEX anticipates issuance of the patent in the spring of 2006.
ADVERTISEMENT
"Protection of our intellectual property is a key part of our ongoing plan for growth," said Jim Griffin, president and CEO of CDEX. "We are pleased that the US Patent office has recognized the uniqueness of our technology."
All current CDEX products, such as the ValiMed(TM) medication validation unit used by hospitals throughout the U.S., are based on applying the same underlying photoelectric technology for which the company has, in addition to this recently announced patent, four additional patents pending. CDEX has also filed corresponding international applications for each of these.
The CDEX ValiMed System offers clinicians a simple and cost-effective tool to ensure medication safety by verifying that medications are correctly compounded. The ValiMed System also validates narcotic returns. ValiMed is sold through the Baxa Corporation, which serves as the exclusive distributor in the United States and Canada of ValiMed Impaired Clinician Solution, ValiMed Regulatory Compliance Solution, and ValiMed Patient Safety Solution.
CDEX core technologies are highly scalable. The company is currently developing products that incorporate the same patent pending technologies currently employed in existing CDEX products for other market segments, including:
1. Security and Public Safety - Identification of substances of
concern (e.g., explosives, illegal drugs, chemical/biological
weapons, and the detection of counterfeit drugs and medications to
assist in the protection of the nation's pharmaceuticals supply);
and
2. Healthcare - Validation of substances and quality assurance
(e.g., validation of prescription and compounded medications to
provide for patient safety, detection of the diversion of
narcotics and controlled substances returned from operating room
suites to the operating room pharmacy, and detection of
counterfeit drugs and medications); and
3. Brand Protection - Detection of counterfeit or sub-par products
for brand protection (i.e., quality assurance inspection of
incoming raw materials, outgoing final products, and products in
the distribution channel).
About CDEX, Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com.
Any statements made in this press release, which contain information that is not historical, are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.
PRESS RELEASE
CDEX APPOINTS NEW DIRECTORS
CDEX Board of Directors Accepts Resignation of Two Directors,
Appoints Two New Directors
Former Chairman of the Board of Directors Steps Down
ROCKVILLE, MD – February 6, 2006 – CDEX, Inc. (CEXI.OB), a public technology development company based in Rockville, Maryland, today announces that Mr. Malcolm Philips, Chairman of the Board of Directors, and Mr. John Knubel, Director, have submitted their resignations to the Board of Directors, effective February 3, 2006. The Board of Directors has accepted their resignations and has appointed James O. Griffin, President and CEO of CDEX, Inc., as an inside Director and Donald W. Strickland, an outside Director, to fill these two vacancies, and serve on the Board until such time as they stand for election at the company’s annual shareholder’s meeting on March 17, 2006. Dr. B. D. Liaw was elected by the Board to succeed Mr. Philips as Chairman of the Board of Directors.
“As Founder, President and CEO, and Chairman of the Board of CDEX, Mr. Philips provided guidance to the company during its difficult start up phase and was a consistent and steadying influence for the company during its transition to a public company. Malcolm leaves behind a strong management team, a strong Board of Directors, and a company poised for growth, all of which are the results of planned succession that he has been implementing during the past year,” said Dr. Liaw. “The Board of Directors thanks Mr. Malcolm Philips for his untiring leadership and unwavering commitment to CDEX over the past four years. As we salute Malcolm and bid him farewell, we wish him success in his pursuits of other interests, and we wish him and his family nothing but the very best in the future.”
“The Board also expresses its thanks for the service provided to it by Mr. John Knubel, who served as the chairman of our financial committee and was our Sarbanes-Oxley compliance consultant,” said Dr. Liaw.
“It is my pleasure to welcome Mr. Donald W. Strickland and Mr. James O. Griffin to our Board of Directors. Don brings a wealth of public company knowledge to our Board and we welcome his insights and experience,” added Dr. Liaw.
Mr. Strickland will serve as the chairman of the financial committee, replacing Mr. Knubel. Mr. Griffin will serve as Secretary of the Board, and a member of the financial committee.
About Donald W. Strickland
Mr. Donald W. Strickland, Director, comes to CDEX from a 30-year career in successfully developing businesses internationally for both large public companies and technology startups. He has held executive positions at Eastman Kodak Company and Apple Computer, including heading product development, manufacturing, and sales. In 1996 he became CEO of PictureWorks Technology, a technology start up, which he sold for $200M in 2000 to IPIX Corporation, a public company traded on the Nasdaq exchange. Thereafter, he served as President and CEO of IPIX through 2004, during which time he led the company through a major restructuring, focusing on the security markets and taking the company to profitability. Mr. Strickland holds a bachelor's degree in physics from Virginia Tech, a master's degree in physics from the University of Notre Dame, a master's degree in optics from the University of Rochester, a master's degree in management from the Stanford University and a law degree from George Washington University.
About James O. Griffin
Mr. James O. Griffin, President & Chief Executive Officer, has served in senior executive positions in the high technology security and defense electronic systems industries for more than 25 years. Throughout his career, Mr. Griffin has focused on commercializing emerging technologies--growing sales and establishing productive distribution channels. Mr. Griffin joined CDEX in 2005, originally as chief operating officer, from a background in both public and private enterprises in the U.S., with extensive experience establishing and heading the international business units of several multinationals, including Sentech, Simplex, and Cardkey Systems. Immediately preceding CDEX, at Cernium, Inc., Mr. Griffin served as vice president of federal systems sales where he founded the company’s Washington, DC office, and opened relationships with government agencies for the developer of security video analytics systems. Previously, as vice president and general manager for the IPIX Corporation, he launched the company’s security division, IPIX Security, and established a customer base that included the 2004 G-8 Summit for the IPIX line of mission critical security imaging systems. As managing director of Simplex Asia Ltd., Mr. Griffin led a nearly two-year transformation of the fire alarm manufacturer’s Asian operations and reversed a major operating loss. Under Mr. Griffin’s leadership, the security services division of Mosler Inc. added contracts with the New York Port Authority to upgrade the security systems in the three airports serving New York City. For Cardkey Systems, Mr. Griffin created the company’s international division, linking together worldwide distributors to form cohesive sales channels. Mr. Griffin holds an MBA from Pepperdine University and a B.S. in Electrical Engineering from California State University.
About CDEX, Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit
www.cdex-inc.com.
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the ability of the Company to raise capital to finance the development of its chemical detection products, the effectiveness, profitability and the marketability of those products, the ability of the Company to protect its proprietary information, the establishment of an efficient corporate operating structure as the Company grows and, other risks detailed from time-to-time in our filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statements.
Here is the link for the Business wire TheBuzzard found and posted. Thanks again.
http://www.quote.com/qc/news/story.aspx?symbols=BB:CEXI&story=200602062351_BWR__BW6197
Mr. Donald W. Strickland, Director, comes to CDEX from a 30-year career in
successfully developing businesses internationally for both large public
companies and technology startups. He has held executive positions at Eastman
Kodak Company and Apple Computer, including heading product development,
manufacturing, and sales. In 1996 he became CEO of PictureWorks Technology, a
technology start up, which he sold for $200M in 2000 to IPIX Corporation, a
public company traded on the NASDAQ exchange. Thereafter, he served as President
and CEO of IPIX through 2004, during which time he led the company through a
major restructuring, focusing on the security markets and taking the company to
profitability. Mr. Strickland holds a bachelor's degree in physics from Virginia
Tech, a master's degree in physics from the University of Notre Dame, a master's
degree in optics from the University of Rochester, a master's degree in
management from the Stanford University and a law degree from George Washington
University.
capnmike: can't post this on RB. Your post that was deleted today, here is another link; http://lifesciences.umaryland.edu/faculty/default.asp?ID=55 I think why he deleted it was because you are getting too close. Im pretty sure he is in that stock that has to do with mad cow brk something like that. Strange how he shows up on RB and problems with posting show up hmmmm. could someone please copy and paste this on RB THX
Thank-You So much...
Bob Zumbrunnan
bobz@investorshub.com
Who is the owner of investorshub? On L. morovans board capnmike, post important info and it gets deleted. I asked who the owner was and that got deleted.Enough is Enough...
Valimed is on Baxa website http://baxa.com/OnlineHelp/valiMed_FAQ.asp
New Press Release
Press Release Source: CDEX, Inc.
Mount Carmel West Hospital Partners with CDEX to Implement ValiMed Medication Validation Solution
Wednesday January 11, 1:45 pm ET
CDEX ValiMed System Chosen by Mount Carmel West to Verify Compounded Medications and Doses, Validate Narcotic Returns, and Screen for Counterfeit Pharmaceuticals
ROCKVILLE, Md. & COLUMBUS, Ohio--(BUSINESS WIRE)--Jan. 11, 2006--Mount Carmel West Hospital has selected the CDEX (OTCBB:CEXI - News) ValiMed system to perform end-product testing of compounded intravenous medications in its pharmacy departments, and validation of returned narcotics in its operating room suites and nursing units. The CDEX ValiMed medication verification system was developed to give clinicians a quick, cost effective, and simple tool to further ensure medication safety by verifying medications are correctly compounded.
ADVERTISEMENT
In a process that takes only seconds, ValiMed uses patent pending technology to validate compounded doses of high-risk medications prior to dispensing. The solution creates an added level of safety in the medication dispensing process, and is also used to validate narcotic returns as well as screen for counterfeit medications.
"Medication safety is our top priority at Mount Carmel and ValiMed enhances the safeguard procedures we currently have in place without adding additional resources. The ValiMed product offers us the opportunity to validate end-products being dispensed from the pharmacy and to validate returned narcotics," said Joe Melucci, Director of Pharmacy at Mount Carmel West.
"CDEX is very excited to be working with Mount Carmel to extend our new validation technology to a community hospital setting," said Jim Griffin, CEO of CDEX.
The CDEX ValiMed solution utilizes a discrete energy source to produce unique return photon signatures, which are referenced against a database of unique medication spectral fingerprints to validate pharmaceuticals. The device validates that the correct medications in the correct amounts have been added to the dose during the compounding process.
About Mount Carmel West
With a history of serving the community since 1886, Mount Carmel offers a broad range of healthcare services in the central Ohio region and treats more than a half million patients each year. The healthcare system includes three hospitals - Mount Carmel East, Mount Carmel West, and Mount Carmel St. Ann's; outpatient services; home care; hospice care; home medical equipment services; an ambulance and mobile intensive care service; a community outreach program for the poor and under-served; a college of nursing; and a Medicare HMO. Mount Carmel is a member of Trinity Health, based in Novi, Michigan. For more information about Mount Carmel, visit the healthcare system's Website at www.mountcarmelhealth.com
About CDEX, Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com.
Any statements made in this press release, which contain information that is not historical, are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.
Contact:
CDEX, Inc.
Media Contact:
Brad Wills, 301-767-1919
bwills@wills-pr.com
OT/Three Arkansas surgeons were playing golf together and discussing surgeries they had performed.
One of them said, "I'm the best surgeon in Arkansas. A concert pianist lost 7 fingers in an accident, I reattached them, and 8
months later he performed a private concert for the Queen of England."
One of the others said. "That's nothing. A young man lost
an arm and both legs in an accident, I reattached them, and 2 years later
he won a gold medal in field events in the Olympics."
The third surgeon said, "You guys are amateurs. Several
years ago a lady was high on cocaine and marijuana and she rode a horse
head-on into a train traveling 80 miles an hour. All I had left to work
with was the horses blond mane and a big ass. Now she's the Senator from
New York."
CDEX 8K Filing
http://www.secinfo.com/d1526c.vj.htm
Thx. I think Griffin will do better, He has 3 different markets Medical, homeland security, Brand Detection. When you read his bio every year he is turning around companies, at a faster pace. Could be with his experience, and connections. With Baxa in place and the need in homeland security, IMO this is undervalued now, We have pasted major milestones. We have been placed in major hospitals, and they are reporting reductions in medications errors. That is what VC look for.Is the product in demand, has it been tested, They also look at the BOD, Do they have experience.Now we have a major medical device company, with a two yr. contract and over 2M in funding, with a proven track record.VC dont care about revenues, They know it will be there. We have 3 different markets with about 10-15 different sources of revenue from each. We will not be 1.00 very long...
Good post. Let's hope Griffin does the same with Cdex, or better!
James Griffin Secured over 6M with-in 6mo. of product launch. http://www.cdex-inc.com/biogriffin.html
I have thanked MP...But I would also like to thank him publically for, IMOP, a job well done. A lesser man would have given up and thrown in the towel..
I have ALWAYS said, and I still say..Malcolm Philips is a man of integrity. I thank him for sticking to the job and bringing us this far..
Thanks, Malcolm...
Godspeed to you and your family.
GO CDEX/ValiMed!!!!!!!!!!!!!!!!!!!!
Inet, that's OK! I just don't want this board to be about anything but Valimed. He is not important. He does nothing to effect the PPS. He only aggrivates the shareholders. He is totally ineffective at anything, but that. In fact, that is all that him and his little group are. Totally inneffective. I read where someone called them-"The Gang That Couldn"t Shoot Straight"!
CDEX/VALIMED is a winner, they are not. That is my last post about that subject. I hope the rest of the loyal long shareholders follow suit. Respond to them anywhere but here. In fact, if they should post here, please ignore there posts!
Others want to see information about Valimed and Cdex, not bickering posts to those that want to hurt the shareholders.
Thanks again, Viking65
Sorry: It got posted
Too sensitive I guess
Posted by: INET6
In reply to: lmorovan who wrote msg# 6535 Date:1/4/2006 10:24:16 AM
Post #of 6543
Imorovan: Where do you get the idea that MP knew he didn't have what it takes to run a company.
He said they were new at it , but that is not inadequacy.
You, I, nor anyone of us have a single clue as to what it would have taken to move things any better than they did.How can anyone say that he admiitedly wasted time. He was CEO ,not the experts that had to develop the technology.
Of course as CEO he could have written all kinds of BS Pr's and boosted the share price, after the stock started trading. Very few of us really wanted that,we wanted a viable company.
What skilled CEO would have taken on the position that MP was in with the reputation they were living down, with no proven product. Can you actually believe someone of Griffin's caliber would take on that problem at that time.
IMO it did not take (five years, as you call it) for MP to swallow his stubborn ambition. it took that time for him to build up a dream dud into something showing success ,enabling him to pridefully back away from. Now he can turn it over to the proper person knowing he has brought it as far as his nursing can bring it.
When are you going to stop cursing the people that saved our investment. Loch was dead and getting deader. Malcolm and Co stepped in and offered a potential solution. Almost no one objected,not even the courts.
The only way the company could get off the ground,and start finalizing a product was to acquire financing. No bank or financial institution would be foolish enough to invest in such a farce(at that Time). The only monies to carry this company forward came from private investors. Private investors (if they have any sense)invest to make money. I'm sure all of them didn't intend to hang around forever,till this company eventually made it.Some sold,that is the name of the game. TO be honest with you I wish I could have been one of them, but I would probably still be hanging on. None the less that is investing,and not rape as you make it sound.
It blows my mind that even after that e mail to ?whoever? when Mp explained his guidance on this project,you as a confessed Christian,can doubt his sincerity. To my knowledge no one, but you, ever questioned his religious leanings,why would he feel compelled to write that to someone of whom he probably wasn't even sure of his leanings.
As it turned out that was his so-long message, and all you could say was "Sure blame God not me". Disgusting to say the least.
As for Griffin, as I recall there was no time table for purchasing those additional shares, the price was locked in . they had an aggreement and monies advanced from Baxe in the works,and maybe sales advances that we have'nt heard about yet. So now there was no immediate financiaal crisis.
By the same token you question Griffin' loyalty to shareholders ,yet earlier in your post you wanted MP to turn the company over to a stranger and would have accepted his loyalty, or did you have someone specific in mind, whether qualified or not.
BAXA ValiMed content states. (Posted by CapnMike)
The best example is an IV, where the only truly effective way to check would be to send a sample to a lab for analysis, adding an unacceptable level of cost and time.
http://www.in-pharmatechnologist.com/news/ng.asp?id=64330\
= = = = = = =
Now, consider that and add what follows (info I learned IN PERSON). Very interesting in my considered opinion !!!!
I attended the first Univ of Michigan poster session and have a short video clip. Hanna Phan was very helpful and informative. The first two med errors that were identified are mentioned on their poster, which states that “at least” two errors have been detected. She shared that they involved Vancomycin. She also verified that just last week a morphine drip concentration error was detected. And consider this…. Hanna said one child was on a dopamine drip and the doctors and nurses were not seeing expected results. They began wondering if the IV was the exact drug and concentration that was ordered, so started to do what most hospitals do…. Send it to the lab for a stat analysis. At that point, they realized they had this particular dopamine signature available in their ValiMed device (keep in mind… a signature is the combination of 1) drug, 2) concentration, and 3) diluent), so instead of the slow and expensive process involved with a stat-lab order, they got what they needed very very quickly and very very cheaply right on the spot!! Yes – the dopamine was exactly what the doctor had ordered, so the lack of expected results was clearly related to something other than a medication error. WOW~!
CDEX, Inc. Appoints James O. Griffin as Chief Executive Officer
New CEO to lead company’s growth strategy in the healthcare, homeland security, law enforcement, and brand protection markets
Rockville, MD -- January 3, 2006– CDEX Inc. (OTCBB: CEXI), the developer of innovative systems for substance detection and verification, announced that James O. Griffin has been named Chief Executive Officer, effective January 1, 2006. Mr. Griffin, who joined CDEX in 2005 as Chief Operating Officer, succeeds Malcolm H. Philips, who will continue as Chairman of the CDEX Board. CDEX (www.cdex-inc.com) is the developer of the ValiMed™ Medication Validation System, distributed by the Baxa Corporation and used by hospital pharmacies to improve patient safety and reduce medication error rates by validating compounded doses of high risk medications. Mr. Griffin, who has an extensive background in developing technology companies in the security industry, will lead the CDEX expansion of its product suite, the company’s entrance into new markets, and the establishment of funding initiatives.
“I look forward to leading the CDEX team as the company strengthens its position in existing markets, expands its product offerings, and leverages its core technologies for new applications in markets such as homeland security, law enforcement, and brand protection,” said James O. Griffin, CEO of CDEX, Inc. “CDEX is fortunate to have a winning combination of strong technologies, highly talented, creative, and devoted personnel, and a loyal investment community. Our vision at CDEX is to save and protect lives, property, and assets through the innovative application of technology for the betterment of society. Bringing this vision to life by building upon the foundation that has been laid by the original founders and investors, and all of the staff at CDEX is a tremendous opportunity and privilege for me.”
Prior to joining CDEX, Mr. Griffin served in senior executive positions in both public and private enterprises, including Cernium, Inc., a leading developer of intelligent video analytics systems, and the IPIX Corporation, where he launched IPIX Security, the company’s video surveillance division. Altogether, Mr. Griffin has more than 25 years of experience in the high technology security and defense electronic systems industries.
CDEX proprietary technologies enable real-time verification of substances s through a process that utilizes a discrete energy source to produce unique return photon signatures to authenticate or validate the substance in question, such as pharmaceuticals, illegal drugs, explosives, distilled spirits, etc. CDEX technologies have applications in a number of fields, including healthcare, where it is being employed to reduce medication error rates, and to reduce the theft of pharmaceutical narcotics. CDEX recently demonstrated its ValiMed™ System’s anti-counterfeiting capabilities at the annual mid-year meeting of the American Society of Health-Systems Pharmacists (Las Vegas, December 4-8, 2005), validating authentic Tamiflu and influenza vaccines and distinguishing these from counterfeit products in seconds using the ValiMed field-portable instrument.
In November 2005, Baxa Corporation, a leading medical device company with relationships with thousands of healthcare institutions, signed a strategic distribution agreement and made a significant investment in CDEX to secure the exclusive distribution rights for the CDEX ValiMed System for healthcare organizations in the United States and Canada. ValiMed is currently the chosen solution of a number of leading healthcare organizations, including the University of Maryland Health Center, the University of Michigan Health System, Texas Children’s Hospital, and the Maricopa Medical Center.
Under Mr. Griffin’s leadership, CDEX will begin implementation of its growth strategy that includes enlarging the company’s intellectual property portfolio, expanding research and development capabilities, accelerating the development and launch of new products, expansion of sales channels, entering selected international markets, setting up strategic business alliances for product development, manufacturing, and service and raising capital for the acquisition of new technologies.
“Jim Griffin’s vision and growth strategy for CDEX is fully supported by the CDEX Board of Directors,” said Malcolm Philips, Chairman of the CDEX Board. “We have been pleased to have Jim at CDEX as our COO, and look forward to his leadership as CEO.”
About CDEX, Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Jim Griffin or Jerry Blair at 301-881-0080 (cdexmanagement@cdex-inc.com).
Followers
|
13
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
86
|
Created
|
12/26/05
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |